TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

If Eli Lilly continues to move lower, a bear put spread would be the best way to trade it. A bear put spread is a debit spread. That means we need to pay the premium to open the t ...

U.S. stocks are rallying after financial markets worldwide got a shot of adrenaline from an encouraging update on U.S.

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...